COMP <GO>
MEDP vs LLY // NET PROFIT MARGIN
Medpace Holdings Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: MEDP 3
— LLY 12
▲ NET PROFIT MARGIN LEADER: LLY
LAST: $652.01 (-3.77%) • MKT CAP: $18.95B
net-margins
17.80%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
net-margins
31.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MEDP VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MEDP | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 83.64% | -42.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 27.90% | 32.36% | -4.46 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 34.0x | 36.4x | -2.42 | MEDP | /valuation <GO> |
| Free Cash Flow Yield | 3.60% | 2.30% | +1.30 | MEDP | /fcf-yield <GO> |
| Operating Margin | 21.10% | 40.21% | -19.11 | LLY | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 17.80% | 31.90% | -14.10 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 20.00% | 45.51% | -25.51 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.13 | 9.29 | -0.16 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.77% | +0.13 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.6 | 77.9 | -23.26 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 0.51 | +0.49 | MEDP | /macro-sensitivity <GO> |
| Forward P/E Multiple | 35.3x | 26.3x | +9.05 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $18.95B | $1.33T | -$1.32T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MEDP REV | LLY REV | MEDP GROSS % | LLY GROSS % | MEDP FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.53B | $65.18B | 44.0% | 83.0% | $681.9M | $16.81B |
| FY 2024 | $2.11B | $45.04B | 44.0% | 81.3% | $572.3M | $8.82B |
| FY 2023 | $1.89B | $34.12B | 44.0% | 79.3% | $348.5M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MEDP // BETA 1.00
LLY // BETA 0.51